The roles of galectin-3 and galectin-4 in the idiopatic Parkinson disease and its progression.

Autor: Cengiz T; Atatürk Training and Research Hospital, Department of Neurology, 06800, Bilkent, Ankara, Turkey. Electronic address: mdtugbacengiz@gmail.com., Türkboyları S; Dr. A.Y. Ankara Oncology Training and Research Hospital, Department of Neurology, 06520, Bilkent, Ankara, Turkey., Gençler OS; Medical Park Hospital, Department of Neurology, 06370 Batıkent, Ankara, Turkey., Anlar Ö; Yıldırım Beyazıt University Faculty of Medicine, Department of Neurology, 06800, Bilkent, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Clinical neurology and neurosurgery [Clin Neurol Neurosurg] 2019 Sep; Vol. 184, pp. 105373. Date of Electronic Publication: 2019 May 22.
DOI: 10.1016/j.clineuro.2019.105373
Abstrakt: Objectives: Idiopathic Parkinson's Disease is a neurodegenerative disease caused by the loss of cells that secrete dopamine in the basal ganglia. Galectins are multipotent, evolutionarily conserved, cell surface glycoconjugated and crosslinked carbohydrate-binding proteins. The roles of these proteins in the diagnosis of the disease have been investigated.
Patient and Methods: Patients who were diagnosed with idiopathic Parkinson's disease were classified as early (stage 1-2) and advanced stage (stage 3-5) according to the Hoehn-Yahr classification. In addition, voluntary cases without parkinson disease constituted the control group. Serum samples of consecutive Parkinson patients and age and gender matched healthy controls were used to measure serum galectin-3 and serum galectin-4 levels. The levels were compared between Parkinson's patients and control groups and early and advanced stage Parkinson's groups.
Results: Thirty age and gender-matched healthy controls and 60 parkinson patients were enrolled in the study. Serum galectin-3 levels were lower in controls compared with patients (892.9 (168.2-2416.3) vs. 2271.8 (375.9-9673.4), respectively, P < 0.01). Serum galectin-3 levels were related to Hoehn-Yahr stages and (r: 0.691, P < 0.001). The early stage group (20 patients) had lower serum galectin-4 levels compared with advanced stages (40 patients) (197.97 ± 46.42 vs. 334.263 ± 37, respectively, P < 0.01). Serum galectin-4 levels were also lower in controls compared with patients 185.1 (116.2-313.3) vs. 282.3 (156.9-984.8), respectively, P < 0.01. ROC analysis showed that serum galectin-3 and galectin-4 were statistically significant in the identification of Parkinson disease and advanced stages. The results were significant for galectin-3 (AUC: 0.89, SE: 0.034, P < 0.001 and CI: 0.823-0.958; P < 0.001) and for galectin-4 (AUC: 0.758, SE: 0.05, P < 0.001).
Conclusion: Serum galectin-3 and galectin-4 may be potential noninvasive markers for the identification of Parkinson disease and advanced stages.
(Copyright © 2019 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: